Junshi Biotech announces cooperation with Wangshan Wangshui to develop oral nucleoside anti-coronavirus drugs

Shanghai, October 4, 2021/PRNewswire/ - On October 4, 2021 Beijing time, Junshi Bio (1877.

Preclinical pharmacodynamic studies have shown that VV116 exhibits significant anti-coronavirus effects both in vivo and in vitro (Cell Research (2021) 0:1–3; https://doi.

Remdesivir has obtained emergency use authorization in some countries for the treatment of new coronary pneumonia, but it can only be administered by intravenous injection

As a leading domestic innovative pharmaceutical company, Junshi Biosciences has been involved in the development of anti-epidemic drugs at the beginning of the outbreak.

About Junshi Bio

Junshi Bio (688180.

Relying on the protein engineering core platform technology, Junshi Bio is at the forefront of international macromolecular drug research and development, and has obtained the first domestic anti-PD-1 monoclonal antibody NMPA approval, the domestic anti-PCSK9 monoclonal antibody NMPA clinical application approval, and the world's first treatment The tumor anti-BTLA blocking antibody was approved by the Chinese NMPA and the US FDA for clinical application, and the phase I clinical study was conducted in China and the United States

About Wangshan Wangshui

Suzhou Wangshan Wangshui Biopharmaceutical Co.

Wangshan Wangshui has built a relatively complete drug innovation system, including functional platforms or entities such as drug design and discovery, drug-ready evaluation, preclinical research, clinical research, drug production, etc.

[1] Geographical scope of cooperation: the global scope except the four regions of Central Asia, Russia, North Africa and the Middle East

[2] https:// https:// -compared-to-placebo-for-patients-with-mild-or-moderat/

Source: Junshi Bio